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Background—We observed that the prodrug clopidogrel was less effective in inhibiting platelet aggregation with
coadministration of atorvastatin during point-of-care platelet function testing. Because atorvastatin is metabolized by
cytochrome P450 (CYP) 3A4, we hypothesized that clopidogrel might be activated by CYP3A4.
Methods and Results—Platelet aggregation was measured in 44 patients undergoing coronary artery stent implantation treated
with clopidogrel or clopidogrel plus pravastatin or atorvastatin, and in 27 volunteers treated with clopidogrel and either
erythromycin or troleandomycin, CYP3A4 inhibitors, or rifampin, a CYP3A4 inducer. Atorvastatin, but not pravastatin,
attenuated the antiplatelet activity of clopidogrel in a dose-dependent manner. Percent platelet aggregation was 3423,
5815 (P0.027), 7410 (P0.002), and 897 (P0.001) in the presence of clopidogrel and 0, 10, 20, and 40 mg of
atorvastatin, respectively. Erythromycin attenuated platelet aggregation inhibition (5512 versus 4212% platelet aggrega-
tion; P0.002), as did troleandomycin (7818 versus 4518% platelet aggregation; P0.0003), whereas rifampin enhanced
platelet aggregation inhibition (3318 versus 5620% platelet aggregation, P0.001).
Conclusions—CYP3A4 activates clopidogrel. Atorvastatin, another CYP3A4 substrate, competitively inhibits this
activation. Use of a statin not metabolized by CYP3A4 and point-of-care platelet function testing may be warranted in
patients treated with clopidogrel. (Circulation. 2003;107:32-37.)
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Clopidogrel inhibits platelet aggregation.1 It decreases theincidence of coronary artery stent thrombosis and is
approved for reduction of myocardial infarction, stroke, and
vascular death in patients with atherosclerotic vascular dis-
ease.2–4 Clopidogrel is an inactive thienopyridine prodrug
that requires in vivo conversion in the liver to an active
metabolite that exerts its antiplatelet effect by forming an
inactivating disulfide bond with the platelet P2Yac (P2Y12)
adenosine diphosphate (ADP) receptor.5–8 The P2Yac ADP
receptor is a guanosine triphosphate (GTP)-coupled 7 trans-
membrane protein that mediates platelet aggregation by
inhibiting adenyl cyclase.8 In rats, it has been suggested that
clopidogrel is activated by cytochrome P450 1A2,6 whereas
an analogue of clopidogrel, CS-747, is speculated to be
activated by human cytochrome P450 3A4 (CYP3A4).9 In
humans, it is not known how clopidogrel is activated.
Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A
(HMG CoA) reductase inhibitor widely used to treat hypercho-
lesteremia. It is metabolized by CYP3A4,10 the most abundant
cytochrome P450 in human liver. Patients with atherosclerotic
disease are frequently treated for hypercholesteremia with both
clopidogrel and atorvastatin or another statin.
During the course of evaluating the effect of clopidogrel on
platelet function using a novel bedside platelet aggregometer, it was
noted that the antiplatelet activity of clopidogrel was diminished
significantly when patients were also taking atorvastatin. This
prompted prospective studies to test the hypothesis that atorvastatin
was inhibiting clopidogrel activation by CYP3A4.
Methods
Patients and Study Protocols
The institutional review board approved the study protocols and
written informed consent was obtained from each subject before
enrollment. In the initial study, 44 patients undergoing successful
elective coronary artery stent implantation received an oral loading
dose of 300 mg of clopidogrel followed by 75 mg/d for 28 days.
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Before stent placement, the patients also received a loading dose of
eptifibatide 180 g/kg followed by a continuous infusion of 2.0 g
· kg1 · min1 for 12 hours. Sixteen patients were not on statin
therapy, 9 were taking 40 mg of pravastatin a day, and 19 were
taking either 10 mg (n7), 20 mg (n7), or 40 mg (n5) of
atorvastatin a day. Platelet aggregation was measured11,12 before
clopidogrel administration and 24 hours later, hours after the
eptifibatide effect was finished.13 Platelet aggregation measurements
were repeated in 13 patients on clopidogrel and in 13 patients on
clopidogrel plus atorvastatin 6 to 8 days after successful stent
implantation.
In the second study, 19 volunteers aged 18 to 40 years were
enrolled in a randomized 30-day protocol to examine the effects of
erythromycin (a CYP3A4 inhibitor) and rifampin (a CYP3A4
inducer) on platelet aggregation in the presence of clopidogrel.
Volunteers were excluded from the study if they had a history of
thrombocytopenia or bleeding disorder or if they were taking any
medications, alcohol, caffeine, tobacco, herbal remedies such as St
John’s wort, grapefruit juice, birth control pills, or charcoal broiled
food. Group 1 (n9) received a maintenance dose of 75 mg/d of
clopidogrel for 6 days, followed by a washout period of 14 days,
followed by 4 days of erythromycin stearate 250 mg 4 times a day,
followed by 6 days of both clopidogrel and erythromycin. Group 2
(n10) was treated similarly, except they received rifampin 300 mg
twice a day instead of erythromycin. Platelet aggregation was
determined on days 0, 6, 20, 24, and 30.
In the third study, the effect of troleandomycin (a CYP3A4
inhibitor) on CYP3A4 activity and platelet aggregation was exam-
ined in 8 volunteers. The exclusion criteria were the same as in the
second study. An erythromycin breath test was performed14 and
platelet aggregation was measured before and 2 hours after ingesting
clopidogrel 450 mg. After a 14-day washout period, the erythromy-
cin breath test and measurement of platelet aggregation were
repeated. Troleandomycin 500 mg was administered, and 1 hour later
450 mg of clopidogrel was ingested. Two hours after clopidogrel, the
erythromycin breath test and platelet aggregation measurements
were repeated.
Platelet Aggregation Measurement
Platelet aggregation was measured with the point-of-care MICROS
cell counter (ABX Diagnostics) and the Plateletworks test platform
(Helena Laboratories). The cell counter uses traditional electronic
impedance cell counting principles.11,12 In brief, a reference platelet
count is performed on 1 mL of fresh whole blood in a Plateletworks
tube containing K3-EDTA as the anticoagulant. The sample is then
passed through the cell counter and the platelet count is determined.
This process is repeated with a second 1 mL sample of fresh whole
blood in a Plateletworks tube containing both citrate and 20 mol/L
ADP. In the presence of ADP, platelets associate and aggregate. As
the aggregated platelets exceed the threshold limitations for platelet
size, they are no longer counted as individual platelets. The ratio of
the platelet count between the agonist and reference tubes is
calculated as percent platelet aggregation. The results are available
within 4 minutes. A previous study comparing this device to light
transmission aggregometry using platelet-rich plasma demonstrated
a correlation coefficient of 0.83 in 225 paired samples.12
Erythromycin Breath Test
The erythromycin breath test (Metabolic Solutions, Inc) was used to
measure hepatic CYP3A4 activity in vivo.14 A preinjection breath
sample was obtained. An intravenous dose of [14C-N-methyl]-
erythromycin (3 Ci, 0.01 mmol of erythromycin) was then admin-
istered. Subsequently, a single breath sample was collected after 20
minutes. Quantitation of exhaled 14CO2 provides a selective measure
of the “instantaneous” hepatic CYP3A4 activity.15 Inhibitors, such as
erythromycin and troleandomycin, and inducers, such as rifampin,
will respectively decrease and increase the percentage of the admin-
istered dose excreted as 14CO2. Troleandomycin was used because it
is a more effective inhibitor of CYP3A4 activity than erythromycin.
Statistics
In patients undergoing stent implantation, unpaired 2-sample t tests
were used to compare platelet aggregation in controls and those
taking atorvastatin. In normal volunteers taking either erythromycin
or rifampin, paired 2-sample t tests with Bonferroni’s correction
were used to compare platelet aggregation between 0, 6, 20, 24, and
30 days within each group. In volunteers undergoing the erythromy-
cin breath test, a paired 2-sample t test was used to compare platelet
aggregation at 0 and 2 hours. Nonparametric data that did not
conform to a normal distribution were analyzed using Mann-
Whitney U tests for unpaired data and Wilcoxon tests for paired data.
All values were expressed as meanSD. A probability value of
0.05 was considered significant.
Results
Patients
There were no differences in age, sex, atherosclerotic risk
factors, or other medications that might promote or inhibit
CYP3A4 in the 3 groups of patients undergoing stent implan-
tation. Other CYP3A4 co-medications (number of patients on
clopidogrel alone/pravastatin/atorvastatin) included diltiazam
(3/1/3), dexamethasone (0/0/1), and phenytoin (0/0/1). Clo-
pidogrel alone inhibited platelet aggregation (Figure 1A).
Coadministration with pravastatin did not influence platelet
aggregation. In the presence of clopidogrel and 10 to 40 mg
of atorvastatin, however, platelet aggregation inhibition was
attenuated. Figure 1B illustrates that atorvastatin produced a
dose-dependent, statistically significant attenuation of the
antiplatelet activity of clopidogrel. Moreover, atorvastatin
administered in a dose of 40 mg/d completely inhibited the
antiplatelet activity of clopidogrel. Inhibition of platelet
aggregation continued to be significantly attenuated 6 to 8
days after stent implantation in patients receiving both clopi-
dogrel and atorvastatin compared with clopidogrel alone
(7413% platelet aggregation versus 4119% platelet ag-
gregation; P0.0001).
CYP3A4 Inhibition and Induction
Clopidogrel inhibited platelet aggregation in normal volun-
teers (Figure 2). Platelet aggregation returned to baseline after
the 14-day washout period. Neither erythromycin nor ri-
fampin altered platelet aggregation. Clopidogrel was signifi-
cantly less active when coadministered with erythromycin, a
CYP3A inhibitor (Figure 2A). Conversely, the antiplatelet
activity of clopidogrel was significantly enhanced by ri-
fampin (Figure 2B).
Erythromycin Breath Test
The in vivo CYP3A4 activity was unambiguously inhibited
by troleandomycin, as measured by the erythromycin breath
test (Figure 3A). Clopidogrel alone inhibited platelet aggre-
gation (Figure 3B). When clopidogrel was administered
during the time CYP3A4 was known to be dysfunctional,
platelet aggregation was not inhibited (Figure 3A and 3B).
Discussion
The overall goal of drug-metabolizing CYP enzymes is the
conversion of lipophilic drugs into more hydrophilic com-
pounds to facilitate elimination by the kidney. This study
showed that clopidogrel is less effective in inhibiting platelet
aggregation when coadministered with atorvastatin, a
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CYP3A4 substrate. In contrast, when clopidogrel was admin-
istered with pravastatin, a hydrophilic drug not metabolized
by the CYP system, platelet aggregation inhibition was not
altered. Furthermore, in vivo studies demonstrated that clo-
pidogrel is metabolized by CYP3A4, the most prominently
expressed CYP in the human liver. We conclude that atorva-
statin, at doses routinely administered to patients, inhibits
CYP3A4 activity in a dose-dependent manner, and thereby
decreases the metabolic conversion of clopidogrel to its
pharmacologically active form.
Clopidogrel is a methyl ester, which is hydrolyzed in vivo
by esterases to an inactive carboxylic acid derivative, which
achieves a peak plasma concentration of 9 mol/L after a
75 mg oral dose. The acid represents more than 85% of the
circulating drug-related compounds in plasma. As a result,
only a small unknown portion of clopidogrel is available for
metabolism to the active metabolite after oral administra-
tion.16 Thus, it is likely that the intrahepatocyte level of
clopidogrel is at least 10-fold lower than the plasma level of
the inactive carboxylic acid form. Atorvastatin is an hydroxy
acid which is reversibly converted to its lactone form in vivo
with approximately equal amounts of lactone and acid in the
serum.17 Atorvastatin acid, but not the lactone, competitively
and selectively inhibits HMG-CoA reductase in the liver,
whereas the more lipophilic atorvastatin lactone is a better
CYP3A4 substrate than atorvastatin acid.10 Approximately
70% of the circulating inhibitory activity for HMG-CoA
reductase has been attributed to atorvastatin acid,18 whereas
atorvastatin lactone rather than the acid form is the relevant
pathway for atorvastatin elimination and drug interactions
because atorvastatin lactone binds more tightly to CYP3A4
than the majority of its other substrates.10,19
Because the degree of competitive inhibition between 2
substrates depends on the relative affinity of the substrates for
the binding site of CYP3A4 and their relative concentrations,
atorvastatin is expected to be a potent inhibitor of many
Figure 1. The in vivo effect of pravastatin and
atorvastatin on the antiplatelet activity of clopi-
dogrel. A, Platelet aggregation before (black col-
umns) and 24 hours after (white columns) clopi-
dogrel administration in patients treated without
or with pravastatin (40 mg) and without or with
atorvastatin (10 to 40 mg). B, The antiplatelet
activity of clopidogrel as a function of the dose
of atorvastatin.
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CYP3A4 substrates if both substrates are present at the same
concentration.19 However, atorvastatin lactone exists at a low
concentration in vivo because its parent compound is so
potent.17 Atorvastatin has previously been shown to inhibit
the metabolism of only a few substrates, such as ethinyl
estradiol,19 which binds CYP3A4 30-fold less tightly than
atorvastatin lactone and is also present in vivo at low
concentrations. Clopidogrel metabolism is inhibited by ator-
vastatin in vivo presumably because clopidogrel occurs at a
low concentration and binds CYP3A4 less tightly than
atorvastatin lactone.
The azole antifungals like itraconazole,20 selected immu-
nosuppressants like cyclosporin, protease inhibitors, macro-
lide antibiotics like erythromycin, and dihydropyridine cal-
cium channel blockers are all potent inhibitors of CYP3A4.
These drugs either bind more tightly to CYP3A4 and/or are
present at significantly higher concentrations than atorvasta-
tin. As a result of their ability to competitively inhibit the
metabolism of atorvastatin, these drugs raise the plasma
concentration of the atorvastatin acid and increase the risk of
myositis and rhabdomyolysis.21 Drugs that inhibit atorvasta-
tin metabolism would, therefore, also be expected to inhibit
clopidogrel metabolism. Other inducers (St John’s wort) and
inhibitors (grapefruit juice) of CYP3A4 should also increase
and decrease, respectively, the activation of clopidogrel.
Lovastatin and simvastatin are metabolized by CYP3A4 and
are predicted to exhibit pharmacological properties similar to
those of atorvastatin.21 In contrast, pravastatin, fluvastatin,
and rosuvastatin are not metabolized by CYP3A4 and would
not be expected to alter clopidogrel activation.21,22
Traditional turbidimetric platelet aggregometry is labor
intensive, is subject to operator variables, and provides
indirect measurements because it uses citrated platelet-rich
plasma devoid of other blood elements. In response to these
limitations, 2 automated point-of-care devices have been
developed that provide rapid and reproducible results using a
small sample of whole blood. One is based on the ability of
platelets to agglutinate fibrinogen-coated beads when acti-
vated by thrombin receptor activating peptide.23 To date, this
device has only been able to measure platelet glycoprotein
IIb/IIIa receptor blockade. The other device, which was used
in this study, uses ADP to promote platelet aggregation and
allowed us the unique opportunity to measure the activity of
clopidogrel, an ADP receptor antagonist.11,12
Drug interactions with other antiplatelet agents have re-
cently been reported. Post-hoc analyses24 have suggested that
aspirin may reduce the benefit of angiotensin-converting
enzyme inhibitors by interfering with their prostaglandin-
Figure 2. Cytochrome P450 3A4 inhibi-
tion and induction. A, The effect of eryth-
romycin on the antiplatelet activity of clo-
pidogrel. B, The effect of rifampin on the
antiplatelet activity of clopidogrel.
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mediated actions on vasodilation, renal perfusion, and vascu-
lar remodeling, although other studies25 dispute this observa-
tion. More recently, it has been reported that ibuprofen
antagonizes the irreversible platelet inhibition induced by
aspirin.26 This study suggests that atorvastatin, but not pra-
vastatin, decreases or prevents clopidogrel from inhibiting
platelet aggregation.
Other investigators have confirmed our preliminary obser-
vations. Clarke and Waskell,27 using genetically engineered
human microsomes, have demonstrated that clopidogrel is
metabolized by human CYP3A4 and that its metabolism is
strongly inhibited by atorvastatin lactone.
It is not known whether the inhibition of clopidogrel
activation by atorvastatin or other drugs increases the risk of
subacute stent thrombosis. First, some of the reduction in this
complication achieved a few years ago was due to technical
improvements in stent expansion rather than to dual antiplate-
let therapy.28 Second, with an incidence of only 1 percent,3 it
would be difficult to recognize the potential impact of drug
interactions on event rates. Third, only a minority of patients
undergoing stent implantation is treated with lipid-lowering
therapy, and most patients on statin drugs are taking low
doses, which have a smaller inhibitory effect on clopidogrel
activation. Finally, statin therapy quickly decreases thrombo-
sis risk and inflammation, and these effects may balance the
loss of clopidogrel efficacy.29–31
Most recently, institution of statin therapy with atorvastatin
80 mg/d before hospital discharge has been encouraged.32,33
If clopidogrel therapy is being instituted, however, it may be
prudent to either initially use a low dose of atorvastatin (or
presumably another lipophilic statin) until the clopidogrel
therapy has ended, or to treat with pravastatin, with the option
of switching to a lipophilic statin at a later date if necessary
to achieve target lipid levels. Two other options, withholding
statin therapy until clopidogrel therapy is completed or
substituting ticlopidine for clopidogrel, are not clinically
attractive. First, aggressive treatment of dyslipidemia to
target goals is strongly recommended for all patients with
coronary artery disease and should not be delayed. Second,
clopidogrel has almost completely replaced ticlopidine ther-
apy because of its favorable side effect profile and once daily
dosing.3
Potential drug interactions with clopidogrel may be partic-
ularly important to recognize in patients diagnosed with acute
coronary syndromes4,34 or treated with coronary brachyther-
apy for in-stent restenosis,35 where clopidogrel may be
prescribed for 6 to 12 months. It has already been suggested
that point-of-care platelet function testing may be necessary
to identify patients who are aspirin resistant.36 Because many
drugs are metabolized by CYP3A4, it is likely that other
drugs may affect the efficacy of clopidogrel, making it even
more important to determine whether platelet aggregation
inhibition targets are being met in individual patients by
point-of-care platelet function testing.
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